VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
+16.26%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$992M
AUM Growth
+$992M
(+28%)
Cap. Flow
+$209M
Cap. Flow
% of AUM
21.1%
Top 10 Holdings %
Top 10 Hldgs %
62.98%
Holding
46
New
6
Increased
7
Reduced
8
Closed
2
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$109M |
| 2 |
SVA
Sinovac Biotech, Ltd
SVA
|
$45M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$23.4M |
| 4 |
AMRS
Amyris Inc.
AMRS
|
$21.8M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$18.6M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$17.4M |
| 2 |
Regenxbio
RGNX
|
$5.91M |
| 3 |
Q32 Bio
QTTB
|
$5.72M |
| 4 |
Codexis
CDXS
|
$5.24M |
| 5 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
$4.85M |
Sector Composition
| 1 | Healthcare | 95.48% |
| 2 | Materials | 4.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $154M | 15.48% | 2,166,832 | – | – |
|
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $109M | 10.95% | +3,792,169 | New | +$109M |
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $77M | 7.76% | 2,049,545 | – | – |
|
|
4
Codexis
CDXS
$246M
| $47.2M | 4.75% | 2,749,343 -305,482 | -10% | -$5.24M |
|
|
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
| $45M | 4.53% | +5,900,000 | New | +$45M |
|
6
Arrowhead Research
ARWR
$3.05B
| $44.6M | 4.5% | 2,328,475 +428,475 | +23% | +$8.21M |
|
|
AMRS
7
DELISTED
Amyris Inc.
AMRS
| $44.3M | 4.46% | 5,575,118 +2,748,407 | +97% | +$21.8M |
|
8
VYNE Therapeutics
VYNE
$8.16M
| $39.5M | 3.98% | 4,011,236 | – | – |
|
|
KDMN
9
DELISTED
Kadmon Holdings, Inc.
KDMN
| $34.9M | 3.52% | 10,454,545 | – | – |
|
|
TCDA
10
DELISTED
Tricida, Inc. Common Stock
TCDA
| $30.3M | 3.05% | 991,711 | – | – |
|
|
11
KalVista Pharmaceuticals
KALV
$678M
| $30.1M | 3.03% | 1,359,149 +1,058,824 | +353% | +$23.4M |
|
|
12
Q32 Bio
QTTB
$20.9M
| $26.5M | 2.67% | 1,159,742 -250,000 | -18% | -$5.72M |
|
13
MEI Pharma
MEIP
$160M
| $24.9M | 2.51% | 5,778,106 -822,554 | -12% | -$3.55M |
|
14
Apellis Pharmaceuticals
APLS
$3.48B
| $24.1M | 2.43% | 1,354,554 -101,945 | -7% | -$1.81M |
|
15
Aclaris Therapeutics
ACRS
$209M
| $23.9M | 2.41% | 1,647,214 | – | – |
|
|
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $21.5M | 2.17% | 1,791,257 | – | – |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $18.7M | 1.88% | 1,492,951 | – | – |
|
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $18.6M | 1.87% | +1,405,476 | New | +$18.6M |
|
|
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $17.9M | 1.8% | 6,619,190 +2,545,000 | +62% | +$6.87M |
|
|
ACER
20
DELISTED
Acer Therapeutics Inc. Common Stock (DE)
ACER
| $17.4M | 1.76% | +565,579 | New | +$17.4M |
|
|
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $16.9M | 1.7% | 937,147 +12,147 | +1% | +$219K |
|
22
Cartesian Therapeutics
RNAC
$261M
| $11.8M | 1.19% | 761,253 -19,348 | -2% | -$301K |
|
23
Galmed Pharmaceuticals
GLMD
$6.96M
| $11.6M | 1.17% | 851,492 +58,785 | +7% | +$798K |
|
24
KALA BIO
KALA
$78.8M
| $10.3M | 1.04% | 1,043,020 | – | – |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $10M | 1.01% | 906,000 | – | – |
|